Disclosure to a Credulous Audience: The Role of Limited Attention

In our model, informed players decide whether or not to disclose, and observers allocate attention among disclosed signals, and toward reasoning through the implications of a failure to disclose. In equilibrium disclosure is incomplete, and observers are unrealistically optimistic. Nevertheless, regulation requiring greater disclosure can reduce observers' belief accuracies and welfare. A stronger tendency to neglect disclosed signals increases disclosure, whereas a stronger tendency to neglect failures to disclose reduces disclosure. Observer beliefs are influenced by the salience of disclosed signals, and disclosure in one arena can crowd out disclosure in other fundamentally unrelated arenas.disclosure; disclosure regulation; limited attention; credulity

On the Forward-Backward Asymmetry of Leptonic Decays of ttˉt\bar{t} at the Fermilab Tevatron

We report on a study of the measurement techniques used to determine the leptonic forward-backward asymmetry of top anti-top quark pairs in Tevatron experiments with a proton anti-proton initial state. Recently it was shown that a fit of the differential asymmetry as a function of $q_{l}\eta_{l}$ (where $q_{l}$ is the charge of the lepton from the cascade decay of the top quarks and $\eta_{l}$ is the final pseudorapidity of the lepton in the detector frame) to a hyperbolic tangent function can be used to extrapolate to the full leptonic asymmetry. We find this empirical method to well reproduce the results from current experiments, and present arguments as to why this is the case. We also introduce two more models, based on Gaussian functions, that better model the $q_{l}\eta_{l}$ distribution. With our better understanding, we find that the asymmetry is mainly determined by the shift of the mean of the $q_{l}\eta_{l}$ distribution, the main contribution to the inclusive asymmetry comes from the region around $|q_{l}\eta_{l}| = 1$, and the extrapolation from the detector-covered region to the inclusive asymmetry is stable via a multiplicative scale factor, giving us confidence in the previously reported experimental results.Comment: 26 pages, 12 figure

Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

KRAS is a commonly mutated gene in advanced colorectal cancer (CRC). Recently, inhibitors of KRAS G12C were developed and have shown promising efficacy for KRAS G12C mutated non-small cell lung cancer. However, KRAS G12C inhibitor monotherapy has not demonstrated excellent efficacy for KRAS G12C mutated advanced CRC due to multiple resistance mechanisms, especially receptor tyrosine kinase (RTK) signaling activation. To overcome this resistance mechanism, various combinations of epithelial growth factor receptor (EGFR) and KRAS G12C inhibitors, including panitumumab plus sotorasib, have been investigated in clinical trials. The combination of EGFR and KRAS G12C inhibitors for KRAS G12C mutated CRC demonstrated overall response rates ranging from 26% to 62.5% in seven clinical trials of phase I to III, whose data are available so far. The median progression-free survival in these trials ranged from 3.9 to 8.1 months. These efficacy data suggest that KRAS G12C inhibitor combination with EGFR inhibitors is more effective for KRAS G12C mutated advanced CRC than KRAS G12C inhibitor monotherapy. They also showed reasonable safety of the combination regimen. Based on these results, phase III clinical trials are being conducted to investigate EGFR and KRAS G12C inhibitor combinations as a first or second-line treatment for KRAS G12C mutated advanced CRC. Furthermore, other KRAS G12C inhibitors, KRAS G12D inhibitors, and pan-RAS inhibitors are being developed, which could make more patients with advanced CRC eligible for KRAS inhibition

Advanced nickel-cadmium batteries for geosynchronous spacecraft

A nickel cadmium battery was developed that can be operated at 80 percent depth of discharge in excess of 10 years in a geosynchronous orbit application, and has about a 30 percent weight savings per spacecraft over present nickel cadmium batteries when used with a 1000 watts eclipse load. The approach used in the development was to replace nylon separators with inert polymer impregnated zirconia, use electrochemically deposited plates in place of conventional chemically precipitated ones, and use an additive to extend negative plate lifetime. The design has undergone extensive testing using both engineering and protoflight cell configurations

KRAS G12C Inhibitor Combination Therapies: Current Evidence and Challenge

Although KRAS G12C inhibitors have proven that KRAS is a druggable target of cancer, KRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to primary and acquired resistance mechanisms. Multiple combinations of KRAS G12C inhibitors with other targeted therapies, such as RTK, SHP2, and MEK inhibitors, have been investigated in clinical trials to overcome the resistance. They have demonstrated promising efficacy especially by combining KRAS G12C and EGFR inhibitors for KRAS G12C-mutated colorectal cancer. Many clinical trials of combinations of KRAS G12C inhibitors with other targeted therapies, such as SOS1, ERK, CDK4/6, and wild-type RAS, are ongoing. Furthermore, preclinical data have suggested additional promising KRAS G12C combinations with YAP/TAZ-TEAD inhibitors, FAK inhibitors, and farnesyltransferase inhibitors. The combinations of KRAS G12C inhibitors with immunotherapies and chemotherapies have also been investigated, and the preliminary results were reported. More recently, KRAS-targeted therapies not limited to KRAS G12C are being developed, potentially broadening the treatment landscape of KRAS-mutated cancers. Rationally combining KRAS inhibitors with other therapeutics is likely to play a significant role in future treatment for KRAS-mutated solid tumors

A Crisis in Clinical Research

The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19 pandemic due to uncovered, systemic inefficiencies across critical processes. Towards initiating discussion on how to reinvigorate clinical research, the Society for Immunotherapy of Cancer (SITC) hosted a virtual summit that characterized issues and formed potential solutions. This commentary serves to highlight the crisis facing clinical research as well as stimulate field-wide discussion on how to better serve patients into the future

Realization of Coherent Optically Dense Media via Buffer-Gas Cooling

We demonstrate that buffer-gas cooling combined with laser ablation can be used to create coherent optical media with high optical depth and low Doppler broadening that offers metastable states with low collisional and motional decoherence. Demonstration of this generic technique opens pathways to coherent optics with a large variety of atoms and molecules. We use helium buffer gas to cool 87Rb atoms to below 7 K and slow atom diffusion to the walls. Electromagnetically induced transparency (EIT) in this medium allows for 50% transmission in a medium with initial OD >70 and for slow pulse propagation with large delay-bandwidth products. In the high-OD regime, we observe high-contrast spectrum oscillations due to efficient four-wave mixing.Comment: 4 pages, 4 figures. V2: modified title, abstract, introduction, conclusion; added references; improved theoretical fit in figure 3(b); shortened slow light theory description; clarified simplicity of apparatus. Final version as published in Phys. Rev.